GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Petra Acquisition Inc (NAS:PAICW) » Definitions » Inventories, Finished Goods

PAICW (Petra Acquisition) Inventories, Finished Goods : $0.00 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Petra Acquisition Inventories, Finished Goods?

Petra Acquisition Inventories, Finished Goods Historical Data

The historical data trend for Petra Acquisition's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petra Acquisition Inventories, Finished Goods Chart

Petra Acquisition Annual Data
Trend Dec19 Dec20
Inventories, Finished Goods
- -

Petra Acquisition Semi-Annual Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Inventories, Finished Goods Get a 7-Day Free Trial - - - - -

Petra Acquisition Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Petra Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Petra Acquisition Inc (NAS:PAICW) » Definitions » Inventories, Finished Goods
Comparable Companies
Traded in Other Exchanges
N/A
Address
5 West 21st Street, New York, NY, USA, 10010
Website
Petra Acquisition Inc is a blank check company.

Petra Acquisition Headlines

From GuruFocus

Petra Acquisition Inc. Announces Pricing of $70 Million Initial Public Offering

By Marketwired Marketwired • 10-08-2020

Petra Acquisition Inc. Announces Closing of $70 Million Initial Public Offering

By Marketwired Marketwired • 10-14-2020

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

By Marketwired Marketwired • 10-25-2021

PETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING

By Marketwired Marketwired • 11-10-2020

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

By Don Li2 Don Li2 • 11-15-2021

Petra Acquisition Inc. Announces Closing of $70 Million Initial Public Offering

By GlobeNewswire GlobeNewswire • 10-13-2020

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

By Marketwired Marketwired • 09-28-2021

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

By GuruFocusNews GuruFocusNews • 12-06-2021

Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

By Business Wire Business Wire • 08-30-2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

By Marketwired Marketwired • 10-04-2021